Y. Tovbin

Is neonatal risk from vasa previa preventable? The 20‐year experience from a single medical center

Vasa previa is a rare condition associated with neonatal morbidity and mortality that may be diagnosed prenatally using transvaginal sonography. The aim of this study was to assess the prenatal detection of vasa previa and its subsequent impact on neonatal outcomes in two 10‐year periods (1988–1997 versus 1998–2007).

A model for second-trimester Down syndrome sonographic screening based on facial landmarks and digit length measurement.

To determine whether Down syndrome can be detected by combining measurements of fetal nasal bone (NB) length, prenasal thickness (PT) and digits 2 and 3 of the hand.

All five digits of the hands of fetuses with Down syndrome are short.

To compare mid‐gestation sonographic measurements of all five digits of the hands of fetuses with Down syndrome with those of normal controls.

Correlation and Overlapping between Nuchal Translucency and Triple Test among Down Syndrome-Affected Pregnancies

Objectives: To examine the correlation and extent of overlapping between first-trimester nuchal translucency (NT) and second-trimester triple test (TT) results in Down syndrome (DS)-affected pregnancies. Methods: Results of both tests were obtained in 28 cases with DS. Inter-test correlation was performed by comparing the likelihood ratios (LRs). Screen-positive rates (risk >1:380) were calculated for different age groups by adjusting age-dependent background risk and tests’ LRs. Overlapping referred to ratio between screen-positive cases by both tests simultaneously and total screen-positive cases by either one or both tests. Results: No correlation was found between the tests’ LRs (Pearson correlation test, r = 0.0487). The overlapping between the tests was 25% and 38.5% among young patients of 20 and 35 years of age, respectively. The average overlapping among patients between 25 and 35 years of age was ∼33%. Only 3 of the 28 DS cases demonstrated LRs <1 by both tests and moreover none exhibited LRs <0.2 by both tests. Conclusions: The degree of overlapping of one third, between NT and TT, confirms the assumption that both tests utilized together improves DS detection. Screen- negative result, by both tests simultaneously, may reassure low-risk population and aid to reduce the number of non-indicated invasive tests.

OP02.23: Vasa previa: early antenatal diagnosis

32–33 weeks of gestation, as well as LHR. Multivariate logistic regression analysis demonstrated that LHR at 22–23 weeks and LHR provided significant independent prediction of survival (OR for LHR at 22–23 weeks = 0.004 (95% CI:0.00–0.13); p = 0.002 and OR for LHR = 0.07 (95% CI:0.01–0.69; p = 0.023). Conclusion: In isolated CDH, LHR measurement at 22–23 as well as at 32–33 weeks provides useful prediction of subsequent survival. The change in LHR between these 2 time points in pregnancy was also predictive of survival and its combination with the LHR at 22–23 weeks showed the highest prediction. Fetuses with low LHR (< 1.0) who have persistent low or decreasing LHR values do the worst in the postnatal period.